Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an announcement.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities, with a total of 2,161,740 securities bought back before the previous day and an additional 109,706 securities bought back on the previous day. This buy-back initiative reflects the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, focusing on providing pathology services. The company offers a range of diagnostic services to medical practitioners, hospitals, and patients across Australia.
Average Trading Volume: 786,194
Technical Sentiment Signal: Buy
Current Market Cap: A$548.7M
See more data about ACL stock on TipRanks’ Stock Analysis page.